ABUS Arbutus Biopharma Corporation
$4.32▲ +0.70%
Healthcare
Other
Volume 1.34M
Avg Volume (10D) 2.39M
Key Metrics & Fundamentals
Market Cap
$662.15M
P/E Ratio
5.5
Div Yield
0.00%
52W Range
3.50 - 5.45
% vs 50 MA
-8.83%
% vs 200 MA
-4.03%
RSI-14
44.8
MACD Histogram
+0.0300
Beta (1Y vs SPY)
1.10
Free Cash Flow
-$6.02M
Gross Rev
$1.01M
Gross Profit
$1.01M
EBITDA
-$4.90M
COGS
–
Operating Exp
$6.77M
Operating Income
-$5.75M
EBIT
-$5.75M
Pretax Income
-$5.14M
Net Income
-$5.14M
EPS (Diluted)
-0.03
Price & Volume History
Loading chart…
Recent News
Arbutus Says US Lifts Clinical Hold on AB-101 Hepatitis B Drug
MT Newswires · Oct 22, 2026 8:10 AM ET
Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor
GlobeNewswire · Oct 22, 2026 7:30 AM ET
Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
GlobeNewswire · Oct 1, 2026 7:30 AM ET
Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
GlobeNewswire · Sep 30, 2026 7:30 AM ET
Health Care Roundup: Market Talk
The Wall Street Journal · Aug 25, 2026 5:18 PM ET
Arbutus Biopharma Launches $230 Million Tender Offer for Common Shares
MT Newswires · Aug 24, 2026 8:33 AM ET
Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share
GlobeNewswire · Aug 24, 2026 7:30 AM ET
Sector Update: Healthcare Stocks Advance Late Afternoon
MT Newswires · Aug 21, 2026 3:48 PM ET
Sector Update: Healthcare Stocks Advance in Afternoon Trading
MT Newswires · Aug 21, 2026 1:43 PM ET
Arbutus Biopharma shares jump after unveiling $230 million share buyback plan
InvestorsHub · Aug 21, 2026 9:32 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See ABUS's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.